A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006605/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To date, there have been no formal clinical studies completed using tiotropium in CF
patients. While there is a large body of evidence demonstrating the efficacy and safety of
tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD), relatively little
is known about its efficacy and safety in patients with a diagnosis of cystic fibrosis.
Therefore, Boehringer Ingelheim proposed to profile the long acting anticholinergic
tiotropium and to generate adequate clinical data for use as a bronchodilator in paediatric
and adult CF. The phase III trial (205.438) is a part of the approved Paediatric
Investigation Plan (PIP) agreed for Spiriva® Respimat® in Cystic Fibrosis.
提供机构：
Vivli
创建时间：
2021-01-27
